Earnings History Data for Exelixis, Inc. (EXEL) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Exelixis, Inc.

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
29-10-2024	AH		EXEL	Exelixis, Inc.	7,950	0.40	0.35	0.00	Exelixis Non-GAAP EPS of $0.47 beats by $0.05, revenue of $539.5M beats by $49.19M [10/29/2024 4:12 PM]	32.42	3.69 (12.86%)	30.95	2.22 (7.73%)	19.20 - 33.32	5,392,439	2,110,000	29,130
Exelixis Non-GAAP EPS of $0.47 beats by $0.05, revenue of $539.5M beats by $49.19M [10/29/2024 4:12 PM] Exelixis raises 2024 revenue guidance as Q3 beats on both lines [10/29/2024 4:41 PM] Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update [2024-10-29 04:05PM] Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [2024-10-30 03:15AM] Exelixis (EXEL) Q3 2024 Earnings Call Transcript [2024-10-30 12:00AM] Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say [Oct-29-24 06:30PM] Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates [Oct-29-24 05:20PM] Exelixis: Q3 Earnings Snapshot [Oct-29-24 04:20PM]
06-08-2024	AH		EXEL	Exelixis, Inc.	7,060	0.75	0.31	0.25	Exelixis beats top-line and bottom-line estimates; raises FY24 revenue outlook [8/6/2024 4:20 PM]	26.43	2.98 (12.71%)	24.99	1.54 (6.57%)	18.64 - 27.09	6,435,785	1,690,000	4,026
FDA accepts Exelixis sNDA for Cabometyx for neuroendocrine tumors [8/6/2024 10:53 AM] Exelixis beats top-line and bottom-line estimates; raises FY24 revenue outlook [8/6/2024 4:20 PM]
30-04-2024	AH		EXEL	Exelixis, Inc.	7,130	0.12	0.22	0.12	Exelixis Non-GAAP EPS of $0.17 misses by $0.12, revenue of $425.2M misses by $35.27M [4/30/2024 4:11 PM]	21.98	-1.48 (-6.29%)	22.10	-1.36 (-5.80%)	18.21 - 24.34	6,612,402	1,960,000	31,300
Exelixis down 7% as Q1 financial results disappoint [4/30/2024 7:20 PM] Exelixis Non-GAAP EPS of $0.17 misses by $0.12, revenue of $425.2M misses by $35.27M [4/30/2024 4:11 PM]
06-02-2024	AH		EXEL	Exelixis, Inc.	6,680	0.27	0.25	-0.09	Exelixis Non-GAAP EPS of $0.33 beats by $0.02, revenue of $480M beats by $2.08M [2/6/2024 4:11 PM]	20.20	-1.62 (-7.44%)	21.40	-0.43 (-1.97%)	16.15 - 24.34	2,803,937	1,870,000	1,144
Exelixis Non-GAAP EPS of $0.33 beats by $0.02, revenue of $480M beats by $2.08M [2/6/2024 4:11 PM]
01-11-2023	AH		EXEL	Exelixis, Inc.	6,440	N/A	0.12	0.23	Exelixis Non-GAAP EPS of $0.10 misses by $0.09, revenue of $471.92M misses by $1.47M [11/1/2023 4:21 PM]	20.11	-0.91 (-4.33%)	20.13	0.02 (0.10%)	15.32 - 22.80	3,455,130	3,360,000	2,557
Exelixis Non-GAAP EPS of $0.10 misses by $0.09, revenue of $471.92M misses by $1.47M [11/1/2023 4:21 PM]
01-08-2023	AH		EXEL	Exelixis, Inc.	6,460	0.25	0.15	0.22	Exelixis Non-GAAP EPS of $0.31 beats by $0.09, revenue of $469.85M beats by $25.02M [8/1/2023 4:11 PM]	20.27	0.64 (3.29%)	19.80	0.17 (0.87%)	14.87 - 22.04	4,210,347	2,230,000	1,593
Exelixis Non-GAAP EPS of $0.31 beats by $0.09, revenue of $469.85M beats by $25.02M [8/1/2023 4:11 PM]
09-05-2023	AH	4:05 PM ET (May 9)	EXEL	Exelixis, Inc.	6,310	0.12	0.17	0.21	Exelixis Non-GAAP EPS of $0.16 misses by $0.06, revenue of $408.8M misses by $13.86M [5/9/2023 4:12 PM]	19.39	0.16 (0.81%)	19.24	0.01 (0.05%)	14.87 - 22.47	3,671,737	2,760,000	7,680
Exelixis Non-GAAP EPS of $0.16 misses by $0.06, revenue of $408.8M misses by $13.86M [5/9/2023 4:12 PM] Exelixis a new overweight at Piper Sandler on Cabometyx, pipeline [5/10/2023 9:40 AM]
07-02-2023	AH	4:05 PM ET (Feb 7)	EXEL	Exelixis, Inc.	5,680	-0.09	-0.13	0.29	Exelixis Non-GAAP EPS of -$0.03 beats by $0.02, revenue of $423.92M beats by $5.21M [2/7/2023 4:10 PM]	17.75	0.46 (2.66%)	17.28	-0.01 (-0.06%)	14.87 - 23.40	2,741,773	2,230,000	1,711
Exelixis Non-GAAP EPS of -$0.03 beats by $0.02, revenue of $423.92M beats by $5.21M [2/7/2023 4:10 PM]
01-11-2022	AH	4:05 PM ET (Nov 1)	EXEL	Exelixis, Inc.	5,350	0.23	0.18	0.12	Exelixis Non-GAAP EPS of $0.31 beats by $0.07, revenue of $411.74M beats by $8.58M [11/1/2022 4:12 PM]	17.00	0.21 (1.22%)	16.80	0.0 (0.00%)	14.87 - 23.40	2,149,823	2,130,000	83,785
Exelixis Non-GAAP EPS of $0.31 beats by $0.07, revenue of $411.74M beats by $8.58M [11/1/2022 4:12 PM] Exelixis Q3 results beat on both lines as it full-year revenue range includes consensus [11/1/2022 4:50 PM] Exelixis brokers two collaboration deals on peptide-drug conjugate and monoclonal antibody [11/1/2022 5:22 PM] Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan [Nov-01-22 04:06PM] Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update [Nov-01-22 04:05PM] Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More [Oct-31-22 04:07PM]
09-08-2022	AH	4:05 PM ET (Aug 9)	EXEL	Exelixis, Inc.	6,690	0.22	0.20	0.30	Exelixis Non-GAAP EPS of $0.28 beats by $0.04, revenue of $419.43M beats by $26.42M [8/9/2022 4:09 PM]	19.50	-1.56 (-7.41%)	21.80	0.74 (3.51%)	15.50 - 23.40	4,776,781	2,110,000	4,249
Exelixis Non-GAAP EPS of $0.28 beats by $0.04, revenue of $419.43M beats by $26.42M [8/9/2022 4:09 PM] Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update [Aug-09-22 04:05PM] Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More [Aug-08-22 09:14AM] Exelixis Stock Undercuts Key Line As Guidance Drags On Quarterly Beat [Aug-10-22 11:37AM] Dow Jones Futures: Inflation Report Looms For Market Rally; Twitter Rallies As Elon Musk Sells More Tesla Stock [Aug-10-22 06:44AM] Exelixis (EXEL) Q2 2022 Earnings Call Transcript [Aug-10-22 12:30AM] Dow Jones Futures: Inflation Report Due As Market Rally Hits Resistance; Trade Desk Soars On Guidance [Aug-09-22 08:42PM] Exelixis (EXEL) Beats Q2 Earnings and Revenue Estimates [Aug-09-22 06:05PM]
10-05-2022	AH	4:05 PM ET (May 10)	EXEL	Exelixis, Inc.	6,880	0.21	0.14	0.00	Exelixis Non-GAAP EPS of $0.26 beats by $0.03, revenue of $355.98M misses by $7.24M [5/10/2022 4:08 PM]	19.84	0.07 (0.35%)	20.87	1.10 (5.56%)	15.50 - 25.77	2,872,289	2,680,000	202
Exelixis Non-GAAP EPS of $0.26 beats by $0.03, revenue of $355.98M misses by $7.24M [5/10/2022 4:08 PM] Exelixis Q1 net income surges nearly 42 times higher on strong Cabometyx sales [5/10/2022 6:59 PM] Why Exelixis (EXEL) Might Surprise This Earnings Season [May-09-22 08:48AM] Exelixis (EXEL) Tops Q1 Earnings Estimates [May-10-22 05:25PM] Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update [May-10-22 04:05PM]
17-02-2022	AH	4:05 PM ET (Feb 17)	EXEL	Exelixis, Inc.	5,880	0.29	0.08	0.09	Exelixis Non-GAAP EPS of $0.35 beats by $0.19, revenue of $451.14M beats by $94.19M [2/17/2022 4:09 PM]	19.55	1.21 (6.60%)	18.65	0.31 (1.69%)	15.50 - 25.77	4,456,664	2,090,000	29,035
Exelixis beats on top and bottom lines, and analysts like what they see (EXEL) [2/18/2022 1:29 PM] Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More [Feb-16-22 09:11AM] Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update [Feb-17-22 04:05PM] Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates [Feb-17-22 05:15PM] Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong [Feb-18-22 12:44PM]
02-11-2021	AH	4:05 PM ET (Nov 2)	EXEL	Exelixis, Inc.	6,860	0.12	0.19	-0.10	Exelixis EPS beats by $0.02, misses on revenue [11/2/2021 4:11 PM]	19.24	-2.64 (-12.09%)	19.60	-2.28 (-10.42%)	16.19 - 25.77	5,143,273	1,550,000	45,405
Exelixis EPS beats by $0.02, misses on revenue [11/2/2021 4:11 PM] Exelixis shares fall after Q3 topline miss, FY forecast [11/2/2021 4:47 PM] Is a Surprise Coming for Exelixis (EXEL) This Earnings Season? [Nov-01-21 10:54AM] Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update [Nov-02-21 04:05PM] Exelixis (EXEL) Q3 Earnings and Revenues Lag Estimates [Nov-02-21 06:25PM] Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript [Nov-02-21 11:01PM] Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View [Nov-03-21 08:56AM] EXEL vs. ILMN: Which Stock Is the Better Value Option? [Nov-03-21 11:40AM] 3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) [Nov-03-21 12:45PM] Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December [Nov-03-21 04:05PM]
05-08-2021	AH	4:05 PM ET (Aug 5)	EXEL	Exelixis, Inc.	5,320	0.30	0.05	0.21	Exelixis EPS beats by $0.24, beats on revenue [8/5/2021 4:08 PM]	17.25	0.25 (1.44%)	17.95	0.95 (5.59%)	16.19 - 27.35	3,490,924	1,760,000	16,693
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer [Aug-05-21 08:00AM] Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update [Aug-05-21 04:05PM] Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates [Aug-05-21 07:15PM] Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript [Aug-06-21 12:01AM] Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View [Aug-06-21 11:29AM] News Flash: Analysts Just Made A Substantial Upgrade To Their Exelixis, Inc. (NASDAQ:EXEL) Forecasts [Aug-06-21 09:13AM]
06-05-2021	AH	4:05 PM ET (May 6)	EXEL	Exelixis, Inc.	7,450	N/A	0.04	0.15	Exelixis EPS misses by $0.03, beats on revenue [5/6/2021 4:15 PM]	25.11	1.89 (8.14%)	23.48	0.26 (1.12%)	18.18 - 27.80	2,107,095	1,430,000	6,280
Exelixis EPS misses by $0.03, beats on revenue [5/6/2021 4:15 PM] Exelixis beats on revenue, but profit narrows in Q1 [5/6/2021 5:00 PM] Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update [May-06-21 04:05PM] Exelixis, Inc. to Host Earnings Call [May-06-21 03:15PM] Exelixis (EXEL) Reports Break-Even Earnings for Q1 [May-06-21 07:05PM] The Smartest Stocks to Buy With $50 Right Now [May-07-21 05:51AM] Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript [May-07-21 11:30AM] Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat [May-07-21 01:04PM]
10-02-2021	AH	4:05 PM ET (Feb 10)	EXEL	Exelixis, Inc.	7,390	0.09	0.03	0.22	Exelixis EPS beats by $0.09, beats on revenue [2/10/2021 4:41 PM]	22.10	-0.93 (-4.04%)	23.00	-0.03 (-0.13%)	13.67 - 27.80	3,576,853	1,841,201	4,914
Exelixis EPS beats by $0.09, beats on revenue [2/10/2021 4:41 PM] Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss [Feb-11-21 03:00PM]
05-11-2020	AH	4:05 PM ET (Nov 5)	EXEL	Exelixis, Inc.	6,520	-0.10	-0.03	0.31	Exelixis EPS beats by $0.03, beats on revenue [11/5/2020 4:09 PM]	20.75	-1.41 (-6.36%)	21.10	-1.06 (-4.78%)	13.67 - 27.80	2,944,566	1,647,300	17,053

06-08-2020	AH	4:05 PM ET (Aug 6)	EXEL	Exelixis, Inc.	7,260	0.21	0.12	0.25	Exelixis EPS beats by $0.11, beats on revenue [8/6/2020 4:09 PM]	22.77	-0.04 (-0.18%)	23.18	0.37 (1.62%)	13.67 - 27.80	821,485	1,814,491	1,849

05-05-2020	AH	4:05 PM ET (May 5)	EXEL	Exelixis, Inc.	7,370	0.15	0.14	0.24	Exelixis EPS beats by $0.02, beats on revenue [5/5/2020 4:10 PM]	25.29	-0.34 (-1.33%)	0.0	0.0 (0.00%)	13.67 - 27.66	3,229,115	4,281,139	0